 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/854
Drugs of Tomorrow 2001: Cancer Overview
|
Description: |
Drugs of Tomorrow 2001: Cancer Overview provides a comprehensive analysis of the current cancer market. The report focuses on the oncology market as a whole, looking at growth factors, class dominance and R&D focus. An in-depth analysis of the cancer pipeline by disease target examines current drugs in development and the key investors in the area for the principal tumor types (breast, brain, colorectal, head and neck, leukemia, lung, ovarian, pancreatic and prostate cancers). areas, with increasing year-on-year sales, the oncology market is becoming an increasingly important area for focus within the pharmaceutical sector. Whilst oncology does not represent the largest segment of the global pharmaceutical market, increasing incidence of the disease, combined with significant sales potential for drugs indicated for cancer ensures that it remains one of the most attractive areas for R&D investment. Cancer offers rich rewards for new and developing therapies, |
|
Contents: |
Report summary
Introduction
Future trends in the prevalence of cancer
Unmet needs in cancer
Investors in cancer
Market share
Disease and class focus
Future market leaders in cancer
R&D opportunities in cancer
CHAPTER 1 THERAPEUTIC CLASS REVIEW
Introduction
Expansion in the cancer market
Therapeutic class review
Defining the cancer market
Cytotoxic therapies
Hormonal therapies
Innovatives therapies
Adjunct therapies
Cancer market segmentation by drug class
Cytotoxics review
Hormonals review
Adjuncts review
Innovatives review
R&D spend and R&D Portfolio size
Investment in Oncology R&D
Therapeutic Focus
Investment in licensing activity in oncology R&D
PIPELINE OVERVIEW
Analysis of the cancer pipeline by drug class
Analysis of the breast cancer pipeline
Analysis of the prostate cancer pipeline
Analysis of the lung cancer pipeline
Analysis of the colorectal cancer pipeline
Analysis of the leukemia pipeline
Analysis of the ovarian cancer pipeline
Analysis of the brain cancer pipeline
Analysis of the pancreatic cancer pipeline
Analysis of the head and neck cancer pipeline
DRUG ANALYSIS
Introduction
Drugs in late stage development for breast cancer
Faslodex
IMC-C225
Gemzar
Theratope
Evista
Drugs in late stage development for prostate cancer
Cetrotide
Provenge
Abarelix
Iressa
Drugs in late stage development for lung cancer
Mitumomab
rhuMAb-VEGF
ISIS 3521
Alimta
Drugs in late stage development for colorectal cancer
Eniluracil (776C85)
SU5416
Thalomid (thalidomide)
Iressa
Gastrimmune
Rubitecan
Drugs in late stage development for leukemia
Glivec (STI 571)
Campath (alemtuzumab)
Nelarabine (GW506U78)
Rituxan (rituximab)
Drugs in late-stage development for ovarian cancer
ZD0473
Rubitecan
Taxotere
Drugs in late stage development for brain cancer
Gliadel wafer
Xcytrin
Cotara
Drugs in late stage development for pancreatic cancer
Irofulven
Avicine
Rubitecan
Drugs in late stage development for Head and Neck cancer
Photofrin
Targretin
IMC-C225
Foscan
KEY INVESTORS IN CANCER R&D
Overview
Cancer players investment in R&D
AstraZeneca
Genentech
Phamacia corporation
BMS
Schering-Plough
FUTURE FOCUS
Future trends in prevalence of cancer
Forecast methodology
Trends in the cancer market to 2007
Expansion of existing classes: cytotoxics and monoclonal antibodies
Increase in the prevalence of cancer
New drug classes: angiogenesis inhibitors and gene therapies
Global cost containment measures
Reformation of Medicare
Patent expiries
Awareness campaigns
Disease management
Increasing participation of older adults in clinical trials
Market forecasts for key cancer types
Breast cancer forecast launches and key drug sales
Forecast drug launches in breast cancer
Forecast sales of the leading pipeline drugs for breast cancer
Prostate cancer forecast launches and key drug sales
Forecast drug launches in prostate cancer
Forecast sales of the leading pipeline drugs for prostate cancer
Lung cancer forecast launches and key drug sales
Forecast drug launches in lung cancer
Forecast sales of the leading pipeline drugs for lung cancer
Colorectal cancer forecast launches and key drug sales
Forecast drug launches in colorectal cancer
Forecast sales of the leading pipeline drugs for colorectal cancer
Leukemia forecast launches and key drug sales
Forecast drug launches in leukemia
Forecast sales of the leading pipeline drugs for leukemia
Ovarian cancer forecast launches and key drug sales
Forecast drug launches in ovarian cancer
Forecast sales of the leading pipeline drugs for ovarian cancer
Brain cancer forecast launches and key drug sales
Forecast drug launches in brain cancer
Forecast sales of the leading pipeline drugs for brain cancer
Pancreatic cancer forecast launches and key drug sales
Forecast launches in pancreatic cancer
Forecast sales of the leading pipeline drugs for pancreatic cancer
Head and neck cancer forecast launches and key drug sales
Forecast launches in head and neck cancer
Forecast sales of the leading pipeline drugs for head and neck cancer
APPENDICES
Research program methodology
SPRINT databases
SPRINT R&D;
Primary Research
Quantification of Data Reliability
Strategic Issues and Opinion Surveys
References
|
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/854
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 16/10/2008 05:46:45 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
Drugs of Tomorrow 2001: Cancer Overview
|
|
Web Address: |
http://www.researchandmarkets.com/reports/854
|
|
Office Code: |
|
OCHKIKMMMVY
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Hard Copy
|
|
€6,591.00 + EUR€ 50.00 Shipping/Handling *
|
|
Electronic
|
|
€6,955.00
|
|
Electronic
- Site License
|
|
€6,527.00
|
* Shipping/Handling is only charged once per order.
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World
|
|
Page 2 of 2
Printed 16/10/2008 05:46:45
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder Name: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World
|
|
|
|
|
|
